MedTrace Logo

Assessment of ANK-700 in Patients With Relapsing Remitting Multiple Sclerosis

NCT04602390 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 34

Last updated 2025-05-31

Study results available
· View outcomes & findings →

Summary

A safety study of ANK-700 in patients with relapsing remitting multiple sclerosis. The study has two parts:

Part A - first in human study in which patients receive a single dose of ANK-700 Part B - patients will receive three doses of either ANK-700 or placebo

Conditions

  • Multiple Sclerosis (MS)
  • Relapsing Remitting Multiple Sclerosis

Interventions

DRUG

ANK-700

Intravenous (IV) infusion

DRUG

Placebo

Intravenous (IV) infusion

Sponsors & Collaborators

  • Anokion SA

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
SEQUENTIAL

Eligibility

Min Age
18 Years
Max Age
60 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-11-06
Primary Completion
2024-04-23
Completion
2024-04-23
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04602390 on ClinicalTrials.gov